Leukemia & Lymphoma
-
Publication Venue For
- Pan-PI3Ki targets multiple B-ALL microenvironment interactions that fuel systemic and CNS relapse.. 62:2690-2702. 2021
- Chronic myelomonocytic leukemia with central nervous system involvement. 59:2267-2268. 2018
- Surveillance imaging in mantle cell lymphoma in first remission lacks clinical utility.. 59:888-895. 2018
- Set alpha/beta-mrna isoform ratio by a novel qpcr assay has prognostic significance in chronic lymphocytic leukemia and may be modulated by treatment. 56:121-122. 2015
- Association of age with fluorescencein situ hybridization abnormalities in multiple myeloma reveals higher rate ofIGH translocations among older patients. 53:2444-2448. 2012
- Quality of life domains among non-Hodgkin lymphoma survivors: an integrative literature review.. 52:972-985. 2011
- Philadelphia chromosome mosaicism at diagnosis in chronic myeloid leukemia: clinical correlates and effect on imatinib mesylate treatment outcome.. 48:2137-2140. 2007
- Pulmonary arterial hypertension and myeloproliferative disorders.. 48:1891-1893. 2007
- High-dose chemotherapy followed by autologous stem cell transplantation for relapsed or refractory Hodgkin lymphoma: prognostic features and outcomes.. 48:1728-1735. 2007
- Single agent bortezomib in the treatment of relapsed and refractory Hodgkin lymphoma: cancer and leukemia Group B protocol 50206.. 48:1313-1319. 2007
- High dose CHOP: a phase II study of initial treatment in aggressive non-Hodgkin lymphoma. Cancer and Leukemia Group B 9351.. 48:870-880. 2007
- Cardiac tamponade in a patient with chronic lymphocytic leukemia.. 48:829-832. 2007
- Excess diagnosis of non-Hodgkin's lymphoma during spring in the USA.. 48:357-366. 2007
- Results of a phase II study of 506U78 in cutaneous T-cell lymphoma and peripheral T-cell lymphoma: CALGB 59901.. 48:97-103. 2007
- The long and winding road of the clinical development of Nelarabine.. 48:1-2. 2007
- Utility of peripheral blood dual color, double fusion fluorescent in situ hybridization for BCR/ABL fusion to assess cytogenetic remission status in chronic myeloid leukemia.. 47:2055-2061. 2006
- Sequential doxorubicin and topotecan in relapsed/refractory aggressive non-Hodgkin's lymphoma: results of CALGB 59906.. 47:1511-1517. 2006
- Venous thromboembolism in patients with diffuse large B-cell lymphoma.. 47:1029-1033. 2006
- Fluorescent in situ hybridization in the diagnosis, prognosis, and treatment monitoring of chronic myeloid leukemia.. 47:397-402. 2006
- Tenascin and microvessel stromal changes in patients with non-Hodgkin's lymphoma are isolated to the sites of disease and vary in correlation to disease activity.. 46:1455-1462. 2005
- Risk of febrile neutropenia among patients with intermediate-grade non-Hodgkin's lymphoma receiving CHOP chemotherapy.. 44:2069-2076. 2003
- Depletion of host reactive T cells by photodynamic cell purging and prevention of graft versus host disease.. 44:1871-1879. 2003
- Fixed-dose pegfilgrastim is safe and allows neutrophil recovery in patients with non-Hodgkin's lymphoma.. 44:1691-1696. 2003
- Alemtuzumab in relapsed or refractory chronic lymphocytic leukemia and prolymphocytic leukemia.. 43:1007-1011. 2002
- Oligonucleotide enhanced cytotoxicity of Idarubicin for lymphoma cells.. 42:417-427. 2001
- Triptolide, a novel immunosuppressive and anti-inflammatory agent purified from a Chinese herb Tripterygium wilfordii Hook F.. 42:253-265. 2001
- High dose cyclophosphamide plus recombinant human granulocyte-colony stimulating factor (rhG-CSF) in the treatment of follicular, low grade non-Hodgkin's lymphoma: CALGB 9150.. 42:1255-1264. 2001
- Post transplant CD8+ gammadelta T-cell lymphoma associated with human herpes virus-6 infection.. 33:377-384. 1999
- Immunomodulatory peptides with high binding affinity for class II MHC molecules for the prevention of graft-versus-host disease.. 23:11-16. 1996
- CD antigens 1993. 13:59-60. 1994
- New CD from the B cell section of the Fifth International Workshop on Human Leukocyte Differentiation Antigens.. 13 Suppl 1:61-64. 1994
- Phase II study of intravenous idarubicin in unfavorable non-Hodgkin's lymphoma.. 10 Suppl:73-79. 1993
- CALGB studies with hematopoietic growth factors in patients with AML. 7:65. 1992
- Assessing physical fitness in treatment-naive and ibrutinib-treated chronic lymphocytic leukemia (CLL) patients 2020
- Phase I trial of lenalidomide in combination with plerixafor for relapsed/refractory chronic lymphocytic leukemia (CLL): follow-up and correlative analysis 2017